Update on the management of patent foramen ovale in 2017: Indication for closure and literature review

Kimberly Calica Atianzar, Peter Casterella, Mig Zhang, Rahul Sharma, Sameer Gafoor

Research output: Contribution to journalArticle

Abstract

Patent foramen ovale (PFO) is a common congenital abnormality with a high prevalence of approximately 25 % in the general population and an even higher incidence of about 40 % in the cryptogenic stroke population. PFO closure in cryptogenic stroke patients as a treatment modality for the secondary prevention of recurrent stroke has been much debated and studied. Several completed randomized clinical trials sought to answer the question of whether PFO closure is beneficial for cryptogenic stroke patients. Until the most recent of these trials, no significant benefit had been demonstrated. Based on newer evidence, in October 2016 the US Food and Drug Administration approved the first dedicated closure device for PFO. This review article describes the association between PFO and cryptogenic stroke, reviews current diagnostic modalities of PFO assessment, discusses management approaches, and reviews randomized clinical trials, practice guidelines, and consensus statements. Associations between PFO and other conditions such as migraine headaches, platypnea-orthodeoxia syndrome, and decompression sickness in divers are also briefly reviewed.

Original languageEnglish (US)
Pages (from-to)75-79
Number of pages5
JournalUS Cardiology Review
Volume11
Issue number2
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Patent Foramen Ovale
Stroke
Randomized Controlled Trials
Decompression Sickness
United States Food and Drug Administration
Secondary Prevention
Migraine Disorders
Practice Guidelines
Population
Equipment and Supplies
Incidence

Keywords

  • Cryptogenic stroke
  • Decompression sickness
  • Migraine
  • Obstructive sleep apnea
  • Patent foramen ovale
  • Patent foramen ovale closure
  • Platypneaorthodeoxia
  • Recurrent stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Update on the management of patent foramen ovale in 2017 : Indication for closure and literature review. / Atianzar, Kimberly Calica; Casterella, Peter; Zhang, Mig; Sharma, Rahul; Gafoor, Sameer.

In: US Cardiology Review, Vol. 11, No. 2, 01.01.2017, p. 75-79.

Research output: Contribution to journalArticle

Atianzar, Kimberly Calica ; Casterella, Peter ; Zhang, Mig ; Sharma, Rahul ; Gafoor, Sameer. / Update on the management of patent foramen ovale in 2017 : Indication for closure and literature review. In: US Cardiology Review. 2017 ; Vol. 11, No. 2. pp. 75-79.
@article{fcf95694413147cfa9851b2f3af884c3,
title = "Update on the management of patent foramen ovale in 2017: Indication for closure and literature review",
abstract = "Patent foramen ovale (PFO) is a common congenital abnormality with a high prevalence of approximately 25 {\%} in the general population and an even higher incidence of about 40 {\%} in the cryptogenic stroke population. PFO closure in cryptogenic stroke patients as a treatment modality for the secondary prevention of recurrent stroke has been much debated and studied. Several completed randomized clinical trials sought to answer the question of whether PFO closure is beneficial for cryptogenic stroke patients. Until the most recent of these trials, no significant benefit had been demonstrated. Based on newer evidence, in October 2016 the US Food and Drug Administration approved the first dedicated closure device for PFO. This review article describes the association between PFO and cryptogenic stroke, reviews current diagnostic modalities of PFO assessment, discusses management approaches, and reviews randomized clinical trials, practice guidelines, and consensus statements. Associations between PFO and other conditions such as migraine headaches, platypnea-orthodeoxia syndrome, and decompression sickness in divers are also briefly reviewed.",
keywords = "Cryptogenic stroke, Decompression sickness, Migraine, Obstructive sleep apnea, Patent foramen ovale, Patent foramen ovale closure, Platypneaorthodeoxia, Recurrent stroke",
author = "Atianzar, {Kimberly Calica} and Peter Casterella and Mig Zhang and Rahul Sharma and Sameer Gafoor",
year = "2017",
month = "1",
day = "1",
doi = "10.15420/usc.2017:18:1",
language = "English (US)",
volume = "11",
pages = "75--79",
journal = "US Cardiology",
issn = "1758-3896",
publisher = "Radcliffe Publishing Ltd.",
number = "2",

}

TY - JOUR

T1 - Update on the management of patent foramen ovale in 2017

T2 - Indication for closure and literature review

AU - Atianzar, Kimberly Calica

AU - Casterella, Peter

AU - Zhang, Mig

AU - Sharma, Rahul

AU - Gafoor, Sameer

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Patent foramen ovale (PFO) is a common congenital abnormality with a high prevalence of approximately 25 % in the general population and an even higher incidence of about 40 % in the cryptogenic stroke population. PFO closure in cryptogenic stroke patients as a treatment modality for the secondary prevention of recurrent stroke has been much debated and studied. Several completed randomized clinical trials sought to answer the question of whether PFO closure is beneficial for cryptogenic stroke patients. Until the most recent of these trials, no significant benefit had been demonstrated. Based on newer evidence, in October 2016 the US Food and Drug Administration approved the first dedicated closure device for PFO. This review article describes the association between PFO and cryptogenic stroke, reviews current diagnostic modalities of PFO assessment, discusses management approaches, and reviews randomized clinical trials, practice guidelines, and consensus statements. Associations between PFO and other conditions such as migraine headaches, platypnea-orthodeoxia syndrome, and decompression sickness in divers are also briefly reviewed.

AB - Patent foramen ovale (PFO) is a common congenital abnormality with a high prevalence of approximately 25 % in the general population and an even higher incidence of about 40 % in the cryptogenic stroke population. PFO closure in cryptogenic stroke patients as a treatment modality for the secondary prevention of recurrent stroke has been much debated and studied. Several completed randomized clinical trials sought to answer the question of whether PFO closure is beneficial for cryptogenic stroke patients. Until the most recent of these trials, no significant benefit had been demonstrated. Based on newer evidence, in October 2016 the US Food and Drug Administration approved the first dedicated closure device for PFO. This review article describes the association between PFO and cryptogenic stroke, reviews current diagnostic modalities of PFO assessment, discusses management approaches, and reviews randomized clinical trials, practice guidelines, and consensus statements. Associations between PFO and other conditions such as migraine headaches, platypnea-orthodeoxia syndrome, and decompression sickness in divers are also briefly reviewed.

KW - Cryptogenic stroke

KW - Decompression sickness

KW - Migraine

KW - Obstructive sleep apnea

KW - Patent foramen ovale

KW - Patent foramen ovale closure

KW - Platypneaorthodeoxia

KW - Recurrent stroke

UR - http://www.scopus.com/inward/record.url?scp=85034041962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034041962&partnerID=8YFLogxK

U2 - 10.15420/usc.2017:18:1

DO - 10.15420/usc.2017:18:1

M3 - Article

AN - SCOPUS:85034041962

VL - 11

SP - 75

EP - 79

JO - US Cardiology

JF - US Cardiology

SN - 1758-3896

IS - 2

ER -